NDA 021447 · Legacy
Zanaflex
Tizanidine Hydrochloride · Oral
Last checked: Nov 20, 2026Latest source record: Nov 22, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2002
Aug 29, 2002
Approved uses
1
Original approval plus efficacy supplements
Registered trials
46
9 Phase 3, 5 recruiting
FAERS reports
18,291
10,734 serious, 898 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jan 2, 2026.
Zanaflex is indicated for the treatment of spasticity in adults. Zanaflex is a central alpha-2-adrenergic agonist indicated for the treatment of spasticity. ( 1 )
Mechanism: Tizanidine is a central alpha-2-adrenergic receptor agonist and presumably reduces spasticity by increasing presynaptic inhibition of motor neurons. The effects of tizanidine are greatest on polysynaptic pathways. The overall effect of these actions is thought to reduce facilitation of spinal motor neurons. 12.2 Pharmacodynamics The CNS depressant effects of tizanidine and alcohol are additive [see Warnings and Precautions ( 5.3 ) and Drug Interactions ( 7.4 )]
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
3 products under this application
- ZANAFLEX · TIZANIDINE HYDROCHLORIDE EQ 4MG BASE · CAPSULE, ORAL · Prescription · TE AB
- ZANAFLEX · TIZANIDINE HYDROCHLORIDE EQ 6MG BASE · CAPSULE, ORAL · Prescription · TE AB
- ZANAFLEX · TIZANIDINE HYDROCHLORIDE EQ 2MG BASE · CAPSULE, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Tizanidine" as an intervention, any sponsor and status, largest first.
- An Artificial Intelligence Driven Approach to Optimize Patient Selection for a Transitional Pain ServicePivotal-lookingNot yet recruiting
University of California, San FranciscoAcademic, hospital or other
NCT07296770 · 474 participants (planned) · Start Oct 1, 2026 · Primary completion Dec 1, 2028
Drug: Pharmacologic Pain Management · For: Postsurgical Pain Management; Postsurgical Pain, Chronic; Opioid Use After Surgery
Sites: San Francisco, California
- CARES (Comprehensive Analgesic, Recovery, and Education Support) for Surgery TrialPivotal-lookingRecruiting
Stanford UniversityAcademic, hospital or other
NCT06027099 · 375 participants (planned) · Start Dec 5, 2024 · Primary completion Jan 2028
Drug: Tizanidine; Placebo · For: Chronic Pain; Back Pain; Neck Pain and 1 more
Sites: Stanford, California; Kansas City, Kansas; Boston, Massachusetts · 4 sites in all
- Ibuprofen Plus Metaxolone, Tizanidine, or Baclofen for Low Back PainPivotal-lookingCompleted
Montefiore Medical CenterAcademic, hospital or other
NCT03068897 · 320 participants · Start May 3, 2017 · Primary completion Jul 11, 2018
Drug: Metaxalone; Tizanidine and 2 more · For: Low Back Pain
Sites: The Bronx, New York
- Addition of Muscle Relaxants in a Multimodal Analgesic Regimen for Analgesia After Primary Total Knee ArthroplastyPivotal-lookingStatus unknown
Rothman Institute OrthopaedicsAcademic, hospital or other
NCT04574791 · 240 participants · Start Sep 3, 2020 · Primary completion Sep 30, 2021
Drug: TiZANidine 2 MG Oral Capsule · For: Pain, Postoperative
Sites: Philadelphia, Pennsylvania
- The Effect of Prolonged Multimodal Analgesic Regimen on Post Hospital Discharge Opioid Use and Pain Control After Primary Total Knee ArthroplastyPivotal-lookingCompleted
Rothman Institute OrthopaedicsAcademic, hospital or other
NCT04003350 · 216 participants · Start Dec 21, 2017 · Primary completion Nov 26, 2018
Drug: Oxycodone; Tramadol and 5 more · For: Osteo Arthritis Knee
Sites: Philadelphia, Pennsylvania
- TIzanidine for the Preventive Treatment of Episodic MigrainE (TIME)Pivotal-lookingStatus unknown
Second Affiliated Hospital, Zhejiang University, School of MedicineAcademic, hospital or other
NCT05484349 · 189 participants (planned) · Start Jun 1, 2023 · Primary completion Dec 25, 2025
Drug: Tizanidine Hydrochloride; Tizanidine Hydrochloride and 1 more · For: Migraine Without Aura; Migraine With Aura
Sites: Luzhou, China; Hangzhou, China; Jiaxing, China · 6 sites in all
- Postoperative Tizanidine Use in Pelvic Reconstructive Surgery: A Pilot StudyPivotal-lookingRecruiting
Hartford HospitalAcademic, hospital or other
NCT07766837 · 186 participants (planned) · Start Aug 21, 2026 · Primary completion Jul 29, 2028
Drug: Tizanidine · For: Post Operative; Post Operative Analgesia; Urogynecologic Surgery
Sites: Hartford, Connecticut
- Efficacy and Safety of Pregabalin/Tizanidine vs. Pregabalin in Patients With FibromyalgiaPivotal-lookingNot yet recruiting
Beijing Tiantan HospitalAcademic, hospital or other
NCT07382921 · 164 participants (planned) · Start Jan 30, 2026 · Primary completion May 2026
Drug: Pregabalin; Pregabalin with tizanidine · For: Fibromyalgia; Pregabalin; Pain
Sites: Beijing, China
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- fatigue1,549
- nausea1,482
- pain1,479
- headache1,431
- drug ineffective1,265
- fall1,047
- dizziness950
- dyspnoea899
- diarrhoea896
- arthralgia824
- vomiting788
- depression777
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 314 |
| 2005 | 356 |
| 2006 | 337 |
| 2007 | 237 |
| 2008 | 314 |
| 2009 | 364 |
| 2010 | 494 |
| 2011 | 521 |
| 2012 | 700 |
| 2013 | 584 |
| 2014 | 727 |
| 2015 | 1,094 |
| 2016 | 1,403 |
| 2017 | 1,034 |
| 2018 | 1,054 |
| 2019 | 1,013 |
| 2020 | 992 |
| 2021 | 867 |
| 2022 | 1,234 |
| 2023 | 1,187 |
| 2024 | 1,249 |
| 2025 | 1,269 |
| 2026 | 946 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Zanaflex (Tizanidine HCl)
2024 spending
$455K
Beneficiaries
216
865 claims
Per beneficiary
$2,104
$3.96 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $485,904 |
| 2021 | $555,937 |
| 2022 | $541,393 |
| 2023 | $503,081 |
| 2024 | $454,553 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Dystonia.
Snaith A, Wade D · BMJ Clin Evid 2014 · Systematic Review
- Trigeminal neuralgia.
Zakrzewska JM, Linskey ME · BMJ Clin Evid 2009 · Systematic Review
- Long-Term Use of Muscle Relaxant Medications for Chronic Pain: A Systematic Review.
Oldfield BJ, Gleeson B, Morford KL, et al. · JAMA Netw Open 2024 · Systematic Review, Research Support, N.I.H., Extramural
- Comparative efficacy and safety of skeletal muscle relaxants for spasticity and musculoskeletal conditions: a systematic review.
Chou R, Peterson K, Helfand M · J Pain Symptom Manage 2004 · Comparative Study, Evaluation Study
- Comparative effectiveness and safety of analgesic medicines for adults with acute non-specific low back pain: systematic review and network meta-analysis.
Wewege MA, Bagg MK, Jones MD, et al. · BMJ 2023 · Systematic Review, Network Meta-Analysis
- Anti-spasticity agents for multiple sclerosis.
Shakespeare DT, Boggild M, Young C · Cochrane Database Syst Rev 2001 · Systematic Review
Sponsor: Legacy
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.